Departure. Clinical Miss. Billion: Should You Bet on Pfizer?
Pfizer faces a trio of headwinds: a CFO departure, a clinical miss, and a billion-dollar bet on Seagen. This article ...
An overview of situations where market-cap weighted benchmarks are appropriate and practical tips for effective performance comparison.
28,411 articlesPfizer faces a trio of headwinds: a CFO departure, a clinical miss, and a billion-dollar bet on Seagen. This article ...
Roku stock jumped Friday on chatter of a potential sale, but the real action could come from a June 22 event investor...
Oklo has zigzagged from a peak near $193 to much lower levels, raising questions about its momentum and prospects. Th...
When markets pull back, investors ask a simple but serious question: should you buy the Invesco QQQ ETF during stock ...
TriSalus investors are eyeing the Q1 2026 earnings update to gauge cash runway, pipeline progress, and milestone-driv...
NuScale Power trades on potential milestones and financing clarity. This guide explains why investors may consider ca...
A recent Insider Form 4 reveals Nayax Ltd.'s President sold 4,500 shares after exercising options. Here’s how to read...
A notable insider transaction at REX raised questions for investors. This guide explains what investors should know, ...
When a CEO unloads a big chunk of stock, investors take note. This article digs into sentinelone's sold over 39,000 s...
MGK's gains have been propelled by a tight core of five megacaps, a dynamic that boosts returns but also raises risk ...
Analysts watch Verrica's 2026 earnings for clues on VP-102 sales, cash runway, and pipeline progress. This guide brea...
SCHB and VTV offer low-cost ways to invest in U.S. stocks, but they serve different purposes. One captures the broad ...